Brauchen wir beim metastasierten Adenokarzinom der Lunge immer eine EGFR-Mutationsanalyse vor der palliativen Firstline-Therapie? Contra

Schlüsselwörter

Lungenkarzinom - Tyrosinkinase Inhibitor (TKI) - Epidermaler Wachstums- faktor Rezeptor (EGFR) - aktivierende Mutation

Keywords

lung cancer - tyrosine kinase inhibitor (TKI) - epidermal growth factor receptor (EGFR) - activating mutation

• Literatur

• 1 Clark GM et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7: 389-394
• 2 Thomas M, Eberhard W et al. REASON: TKI sensitive EGFR mutation status and associated characteristics of advanced NSCLC patients - Results from a German registry. Onkologie 2011; 34 (Suppl 6) Abstract V451
• 3 Keedy VL et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-2127
• 4 Shepherd FA et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005; 353: 123-132